Swiss biotech AC Immune has said that its vaccine-like alpha-synuclein-targeted immunotherapy has shown promise in slowing down the progression of Parkinson's disease. The results of the phase 2 ...

Sio Gene Therapies' litany of clinical disappointments over the last few years has finally led to the demise of the biotech, formerly known as Axovant and one of the 'vant' companies originally ...

Sanofi said this morning that its pipeline includes 12 potential blockbuster drugs that could generate more than €10 billion ($11 billion) in annual sales by the end of the decade, a sharp increase on ...

Bayer has its first regulatory approval for elinzanetant as a non-hormonal treatment for menopausal symptoms – in the UK – as it chases down a rival therapy from Astellas. The Medicines and Healthcare ...

Walmart is the latest US retail pharmacy giant to announce its intention of disrupting the clinical trials category, with the launch of a new institute that pledges to increase and diversify community ...

Months of uncertainty have come to a close. The BIOSECURE Act, now part of the National Defense Authorization Act (NDAA), will put in motion US government-wide restrictions on ‘biotechnology companies ...

Moderna's mRNA-based pandemic flu vaccine – which had federal funding pulled earlier this year amid an increasingly vaccine-sceptic stance by the Trump administration – has been thrown a lifeline by ...

The next two discretionary priority vouchers to be awarded by the FDA are reported to be heading for two MSD candidates with blockbuster potential. According to Reuters, MSD – known as Merck & Co in ...

A California jury has awarded $40 million in damages to two women who sued Johnson & Johnson, claiming that its talc-based Baby Powder product led to their ovarian cancer. The jury in a Los Angeles ...

Merck KGaA has teamed up with Flagship Pioneering's Valo Health on an ambitious project to apply AI to the discovery of novel drug targets and therapeutics for Parkinson's disease. The partnership ...

The FDA has published new guidance aimed at reducing or stopping toxicity studies of monoclonal antibody-based drugs in non-human primates (NHPs), in the latest stage of an ongoing effort to reduce ...

EVERSANA has launched a new pharmacovigilance (PV) platform that answers the need to apply advanced data analytics and artificial intelligence to drug safety monitoring and risk management. The new ...